Office use: the regulatory definition, and the two layers that decide it

The definition, as a state writes it

Illinois puts the definition in its compounding rule, and the second sentence is the one worth reading twice:

"Office use" means the administration of a non-patient specific compounded drug to a patient by a practitioner in the practitioner's office or by the practitioner in a health care facility or treatment setting. "Office use" does not include a pharmacy's delivery of a compounded drug to a prescribing practitioner's office pursuant to a valid patient-specific prescription.

Texas defines the term in its statute in nearly the same words, adding the settings it reaches:

"Office use" means the provision and administration of a compounded drug to a patient by a practitioner in the practitioner's office or by the practitioner in a health care facility or treatment setting, including a hospital, ambulatory surgical center, or pharmacy in accordance with Chapter 563.

What the term excludes, and why that matters

The Illinois exclusion is the most useful sentence in either definition. A pharmacy that ships a preparation to a prescriber’s office against a prescription written for a named patient has not engaged in office use, however much the delivery looks like restocking a cabinet. The parcel arrives at the same address either way; what differs is whether a patient was identified before the preparation was made.

That distinction is why "we deliver to your office" answers nothing on its own. Two arrangements produce that sentence, and only one of them is the term defined above.

Both layers have to say yes

What the words mean is settled by the definitions. Whether the arrangement is available to you is decided in two places, independently.

The state board of pharmacy decides whether a pharmacy it licenses may send non-patient-specific stock to a prescriber at all, and the answers across the states reviewed on this site run from an express prohibition to a permission confined to veterinarians. Those verdicts are set out state by state in the office-use guide and summarised in is office use compounding legal.

Federal law decides separately. The exemption at § 353a opens with a condition — the drug product must be "compounded for an identified individual patient based on the receipt of a valid prescription order" — so a preparation made for nobody in particular is outside it by its own terms. Several state rules make their permission expressly subject to applicable federal law, which routes the question straight back to that sentence.

The route that carries stock with no patient named at the federal level is the other pathway: a 503B outsourcing facility, which is why so many state rules name it by number. What the two pathways trade against each other is set out in 503A vs 503B, and the practical sequence in how to place an office-use order.

Not the same as compounding ahead of an order

The arrangement most often confused with this one is anticipatory compounding, which has an express federal basis that office use does not. It changes when a preparation may be made, not who may receive it, and the stock stays inside the pharmacy until a patient-specific prescription arrives. The two are compared at length in anticipatory compounding vs office use.

The other pairing worth keeping separate is this arrangement against the ordinary one: a prescription compounded for a named patient and delivered to your office is not office use, and did not become stock by arriving. That distinction, and everything it decides, is at office stock and patient-specific fulfilment compared.